NASDAQ:VALN Valneva Q4 2025 TU Earnings Report $5.74 -0.16 (-2.71%) Closing price 04:00 PM EasternExtended Trading$5.78 +0.04 (+0.70%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Valneva EPS ResultsActual EPS-$0.68Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AValneva Revenue ResultsActual Revenue$55.92 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AValneva Announcement DetailsQuarterQ4 2025 TUDate2/15/2026TimeBefore Market OpensConference Call DateThursday, February 19, 2026Conference Call Time1:00AM ETUpcoming EarningsValneva's Q3 2026 earnings is estimated for Thursday, November 19, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Valneva Earnings HeadlinesSepterna (NASDAQ:SEPN) vs. Valneva (NASDAQ:VALN) Financial ReviewSeptember 26, 2026 | americanbankingnews.comFootball fundraiser collects £2k for Livingston charity Team Jak FoundationSeptember 22, 2026 | msn.comIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.October 2 at 1:00 AM | Banyan Hill Publishing (Ad)Pfizer (PFE), Valneva (VALN) Lyme Vaccine Moves to EMA Review Despite Phase 3 CaveatSeptember 15, 2026 | insidermonkey.comPotential Moderna-style share surge? Takeover candidates Evotec, Valneva and Vidac Pharma in focus — analysts bullishSeptember 1, 2026 | msn.comAnswers to 3 questions about a potential Lyme vaccineAugust 28, 2026 | msn.comSee More Valneva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Valneva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Valneva and other key companies, straight to your email. Email Address About ValnevaValneva (NASDAQ:VALN) SE is a specialty vaccine company focused on developing, manufacturing and commercializing vaccines for infectious diseases with significant unmet medical needs. The company combines research and development capabilities with commercial vaccine operations and serves travelers, public-health programs and other markets through products distributed in multiple countries. Valneva’s marketed portfolio has included IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain forms of travelers’ diarrhea. The company also developed IXCHIQ, a vaccine targeting chikungunya, and continues to advance vaccine candidates for diseases including Lyme disease. Product availability and regulatory approvals vary by geography. Valneva was formed in 2013 through the merger of Austria-based Intercell and France-based Vivalis. Its operations and research activities have included facilities in France, Austria, Sweden, Scotland and Canada, supporting development and supply for international markets. The company is headquartered in France and is listed on Euronext Paris and, through American depositary shares, on the Nasdaq Global Select Market under the symbol VALN.View Valneva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
